ATAI Life Sciences N.V. Aktie News

Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, with AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) a direct beneficiary. As reported by J&J on Wednesday, Spravato's fourth quarter 2025 sales in treatment-resistant depression (TRD) rose 10% sequentially...

Last year, the biotechnology industry leaned heavily into the power of artificial intelligence (AI), using machine learning models to identify drug targets, to optimize molecules, and to make key predictions about trial outcomes. Alongside the continued proliferation of technology within the drug development space, companies with a focus on obesity, rare diseases, and oncology applications saw ...

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it participated in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held January 12 to 15, 2026, in Nassau, The Bahamas, where the company presented two scientific posters and delivered a Hot Topic Presentation. The clinical-stage biotechnology company said the presentations included new clinical and precli...

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced its participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took p...

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) has outlined its outlook for 2026, highlighting anticipated clinical milestones and recent corporate developments ahead of its participation in the JP Morgan 44th Annual Healthcare Conference in San Francisco later this month. The clinical-stage biotechnology company said it enters 2026 following the completion of the strategic combination of atai Life Sc...

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, ...

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has completed the redomiciliation of its parent company from the Netherlands to the United States, with the new entity incorporated in Delaware. The move was approved by approximately 99% of the votes cast at the company's extraordinary general meeting of shareholders held on November 4.

AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that its common stock has been added to the Nasdaq Biotechnology Index (NBI), effective prior to the market open on December 22. The NBI is designed to track the performance of biotechnology and pharmaceutical companies listed on the Nasdaq Stock Market that meet specific eligibility criteria, including minimum market capitalization, average dai...